trending Market Intelligence /marketintelligence/en/news-insights/trending/pa-Hshv0LZE4nIqEVZM5zA2 content esgSubNav
In This List

Glenmark secures US FDA approval for another generic hypertension drug

Case Study

Identifying PPE Suppliers During the Pandemic

Blog

Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage

Blog

Fintech Intelligence Digital Newsletter: May 2021

Video

COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021


Glenmark secures US FDA approval for another generic hypertension drug

Glenmark Pharmaceuticals Ltd. secured U.S. Food and Drug Administration approval to market a generic version of Allergan PLC's hypertension drug Bystolic.

Glenmark will launch its Nebivolol tablets three months before Bystolic's patent expires as part of a settlement agreement with Allergan.

Bystolic generated annual sales of $1 billion in the 12-month period ending March 2017, according to IMS Health Holdings Inc. data.

Glenmark Pharmaceuticals also recently secured U.S. FDA approval to market a generic version of Benicar, Daiichi Sankyo Co. Ltd.'s hypertension drug.